

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

SEP 10 2007

(use as many sheets as necessary)

## Sheet

1

**of**

2

**COMPLETE IF KNOWN**

<b>Application Number</b>	<b>10/550,968</b>
---------------------------	-------------------

<b>Filing Date</b>	<b>September 26, 2005</b>
--------------------	---------------------------

<b>First Named Inventor</b>	Mark E. Duggan
-----------------------------	----------------

Group Art Unit	1621
----------------	------

**Examiner Name**

**Attorney Docket Number** 21298P

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

9/21/07

\* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/550,968	
			Filing Date	September 26, 2005	
			First Named Inventor	Mark E. Duggan	
			Group Art Unit	1621	
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21298P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
AK		Chemical Abstracts Service, Columbus Ohio, US; XP002438782, retrieved from STN Accession No. 1962:12809, Database Accession No. 56:12809, RNs: 93323-83-2 and 98742-49-5.
		J. A. O'Brien et al., "A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain" J. of Pharmacology and Experimental Therapeutics, 2004, Vol. 309, No. 2, pgs. 568-577.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438783, Database Accession No. BRN:3376420.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438784, Database Accession No. BRN:344532.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438785, Database Accession No. BRN:3461782.
		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438786, Database Accession No. BRN:2731365.
AK		Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; XP002438787, Database Accession No. BRN:2809287.

Examiner Signature	S. Kumar	Date Considered	9/21/07
--------------------	----------	-----------------	---------

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	1009 Rec'd PTO/PTO
				Filing Date	September 26, 2005
				First Named Inventor	Mark E. Duggan, et al.
				Group Art Unit	1691
				Examiner Name	S. Kumar
Sheet	1	of	1	Attorney Docket Number	21298P

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005